Phaseline

Targets › SMOC2

SMOC2 (SPARC-related modular calcium-binding protein 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Metabolic and endocrine; next expected readout May 2027.

Promotes matrix assembly and cell adhesiveness (By similarity). Can stimulate endothelial cell proliferation, migration, as well as angiogenesis. (UniProt, Q9H3U7)

Open in Phaseline: the race on SMOC2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mediar TherapeuticsMTX-439
Anti-SMOC2 monoclonal antibody
SMOC2Phase 1Healthy Adult ParticipantsMay 2027

Conditions

Healthy Adult Participants (1)

Modalities

protein or peptide (1)

Companies

Mediar Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.